Lenvatinib increases progression free survival when used with everolimus in metastatic renal cell carcinoma

Bookmark and Share
Published: 9 Jun 2015
Views: 2335
Dr James Larkin - Royal Marsden Hospital, London, UK

Dr Larkin talks to ecancertv at ASCO 2015 about the results of a randomised phase II trial of kinase inhibitor lenvatinib used in combination with everolimus in renal cell carcinoma, which saw significant improvements in progression free survival compared with everolimus alone.

See the news story for more.